• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Freeline Therapeutics Holdings plc

    3/1/24 4:05:32 PM ET
    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRLN alert in real time by email
    15-12G 1 d757703d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001-39431

     

     

    Freeline Therapeutics Holdings plc

    (Exact name of registrant as specified in its charter)

     

     

    Sycamore House

    Gunnels Wood Road

    Stevenage, Hertfordshire SG1 2BP

    United Kingdom

    +44 (0)1438 906870

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    American Depositary Shares, each representing fifteen ordinary shares,

    Ordinary shares, nominal value £0.00001 per share *

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

     

    *

    Not for trading, but only in connection with the registration of the American Depositary Shares.

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: one

     

     

     


    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Freeline Therapeutics Holdings plc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

    Date: March 1, 2024

     

    FREELINE THERAPEUTICS HOLDINGS PLC
    By:  

    /s/ Michael J. Parini

    Name:   Michael J. Parini
    Title:   Chief Executive Officer
    Get the next $FRLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FRLN

    DatePrice TargetRatingAnalyst
    2/1/2022Overweight → Equal-Weight
    Morgan Stanley
    1/7/2022Neutral → Buy
    Redburn
    11/29/2021$10.00Buy
    BTIG
    8/18/2021$30.00 → $20.00Buy
    HC Wainwright & Co.
    8/17/2021$27.00 → $8.00Overweight → Neutral
    JP Morgan
    8/17/2021Overweight → Neutral
    JP Morgan
    More analyst ratings